GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Myriad Genetics Inc.
Myriad Genetics is a pioneer in genetic testing. Its stock price reflects its initial success with breast cancer tests and subsequent struggles with competition and falling prices. The chart reflects the company's efforts to diversify and find new growth drivers.
Share prices of companies in the market segment - Cancer analysis
Myriad Genetics is a pioneer in genetic testing, offering tests to determine the risk of hereditary cancer. We have classified the company as a "Cancer Analysis" company. The chart below shows how the market views the prospects for personalized medicine and genetic diagnostics.
Broad Market Index - GURU.Markets
Myriad Genetics is a pioneer in genetic testing, offering tests to determine the risk of hereditary cancer. Its innovation has earned it a place in the GURU.Markets index. The chart below compares its performance, reflecting investor expectations, with the overall market picture.
Change in the price of a company, segment, and market as a whole per day
MYGN - Daily change in the company's share price Myriad Genetics Inc.
For Myriad Genetics, a pioneer in genetic testing, change_co is a measure of the volatility inherent in the medical technology sector. Daily fluctuations reflect the response to pricing changes and the launch of new tests. This metric is important for analyzing innovative diagnostic companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer analysis
Myriad Genetics, Inc. is a pioneer in genetic testing. This chart highlights the sector's high volatility. Comparing it to MYGN, which focuses on cancer diagnostics, helps assess how sensitive its business is to competition.
Daily change in the price of a broad market stock, index - GURU.Markets
Myriad is a pioneer in genetic testing for hereditary cancer risk assessment. The oncology diagnostics sector is extremely sensitive to clinical data and competition. The chart below shows the volatility in this niche, reflecting both high expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Myriad Genetics Inc.
Myriad Genetics is a pioneer in genetic testing. Its year-over-year performance reflects rapid growth in testing volumes and investor confidence in the potential of its technologies for early disease diagnosis. The chart below chronicles the history of this science-intensive business.
Annual dynamics of market capitalization of the market segment - Cancer analysis
Myriad Genetics, Inc. is a pioneering company in genetic testing, specializing in hereditary cancer diagnostics. This chart shows how its efforts to diversify its testing portfolio and the intense competition in the rapidly evolving field of genetics are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Myriad, a pioneer in genetic testing, is a growth story in healthcare. Its stock price is driven not by the economy, but by testing volume, insurance coverage, and competition. The chart reflects how the company is trying to regain leadership in the market it created.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Myriad Genetics Inc.
Gladstone Commercial, a REIT that owns a portfolio of office and industrial properties, displays monthly fluctuations in the chart, reflecting the stability of its rental income, which is secured by long-term contracts with tenants. This makes it less volatile than other types of REITs.
Monthly dynamics of market capitalization of the market segment - Cancer analysis
Myriad Genetics is a pioneer in molecular diagnostics and genetic testing, particularly in oncology. The dynamics of this sector depend on scientific breakthroughs, insurance reimbursement policies, and competition. The chart below shows how investors assessed the prospects for personalized medicine and genetic diagnostics.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Myriad Genetics, Inc. is a pioneer in genetic testing and precision medicine, offering tests to determine the risk of hereditary cancer. The company's future depends on innovation and reimbursement policies. A broad market chart allows us to assess the extent to which its stock, driven by scientific and regulatory news, has lived a life of its own, independent of overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Myriad Genetics Inc.
Myriad Genetics is a pioneer in genetic testing. Its weekly stock price reflects testing volumes, changes in insurance reimbursement rates, and competition in the rapidly growing genetic diagnostics market.
Weekly dynamics of market capitalization of the market segment - Cancer analysis
Myriad Genetics is a pioneer in genetic testing. Comparing its weekly performance with the healthcare sector reveals its volatility. The chart shows how competition and changes in insurance rates cause its stock to move differently from other diagnostic companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Myriad, a diagnostics company, shares live in a world of their own. Their performance is determined by the decisions of insurance companies. A chart comparing them to the S&P 500 clearly demonstrates how the stock can move independently of the broader market.
Market capitalization of the company, segment and market as a whole
MYGN - Market capitalization of the company Myriad Genetics Inc.
The market capitalization of Myriad Genetics is the saga of a genetic testing pioneer. The company's trajectory, known for its BRCA breast cancer risk test, reflects its struggle with competition after patent expirations and attempts to diversify into other diagnostic areas. It's a visualization of how an innovator is forced to adapt to survive.
MYGN - Share of the company's market capitalization Myriad Genetics Inc. within the market segment - Cancer analysis
Myriad Genetics was one of the first companies to offer genetic testing for hereditary cancer predisposition. Its market share reflects its pioneering status and continued competition in the molecular diagnostics market. The chart below shows the weight of this veteran in personalized medicine.
Market capitalization of the market segment - Cancer analysis
Myriad Genetics is a pioneer in genetic testing, known for its tests for hereditary cancer risk. The chart below shows the overall market capitalization of the cancer testing sector. Its dynamics reflect the growing role of genetics in personalized medicine and disease prevention.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Myriad Genetics line on this chart represents the history of genetic testing. The company pioneered BRCA cancer predisposition testing. Its market capitalization reflects both its past successes and the intense competition and pricing pressure in this mature medical diagnostics market.
Book value capitalization of the company, segment and market as a whole
MYGN - Book value capitalization of the company Myriad Genetics Inc.
Myriad Genetics' capital lies in its laboratories and intellectual property for genetic tests for determining predisposition to hereditary diseases, primarily cancer. This represents its scientific and diagnostic capital. The chart shows how this pioneer in genetic testing manages its capital in the face of increasing competition and changing patent laws.
MYGN - Share of the company's book capitalization Myriad Genetics Inc. within the market segment - Cancer analysis
Myriad Genetics is a pioneer in genetic testing. The company's strength lies in its extensive database and certified laboratories where samples are analyzed. The graph shows the share of the physical laboratory infrastructure for molecular diagnostics that the company controls.
Market segment balance sheet capitalization - Cancer analysis
Genetic testing like Myriad's requires high-tech laboratories. Compared to its healthcare assets, this makes the company moderately capital-intensive. Its diagnostic services rely on complex and expensive physical infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Myriad Genetics' book value reflects its cutting-edge laboratories that conduct genetic testing to determine hereditary cancer risk and tailor treatments. The company's assets reflect its technological platform and scientific potential as a pioneer in molecular diagnostics. The chart demonstrates its scale in this important medical niche.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Myriad Genetics Inc.
Myriad Genetics, a pioneer in genetic testing, is valued at a premium to its laboratories. Investors are paying for its brand, its scientific heritage, and its potential for growth in new areas such as pharmacogenomics and prenatal diagnostics.
Market to book capitalization ratio in a market segment - Cancer analysis
Myriad Genetics is a pioneer in genetic testing, particularly for cancer risk assessment. Its value lies in its scientific data and technology. The chart shows how the market assesses its ability to compete in a rapidly growing but increasingly competitive market.
Market to book capitalization ratio for the market as a whole
Myriad Genetics is a pioneer in genetic testing, known for its cancer predisposition tests. The company faces increasing competition. This metric reflects how investors assess its ability to innovate and maintain market share in the market it helped create, but which is becoming increasingly competitive.
Debts of the company, segment and market as a whole
MYGN - Company debts Myriad Genetics Inc.
Myriad Genetics, a pioneer in genetic testing, uses capital to fund R&D and commercialization of new diagnostic tests. In an environment of increasing competition and pricing pressure, managing finances and debt is becoming increasingly important. This chart reflects its investments in maintaining scientific leadership.
Market segment debts - Cancer analysis
Myriad Genetics is a pioneering molecular diagnostics company, best known for its BRCA test. The genetic testing market has become highly competitive. This chart shows how the company manages its capital to invest in new tests and compete with new players in the rapidly evolving industry.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Myriad Genetics Inc.
Myriad Genetics is a pioneer in genetic testing and personalized medicine, known for its cancer predisposition tests. To remain at the forefront of science, the company must continually invest in research and new technologies. This chart shows how it uses debt to fund innovation in the rapidly evolving field of genomics.
Market segment debt to market segment book capitalization - Cancer analysis
Myriad Genetics was one of the first companies to offer genetic testing to determine the risk of hereditary cancer. It's a highly competitive market. This chart shows how the company finances its research and laboratory capacity. It compares its debt to the market capitalization of the entire medical diagnostics sector, reflecting its financial strategy.
Debt to book value of all companies in the market
Myriad Genetics is a pioneer in genetic testing, helping assess the risk of hereditary diseases, including cancer. Medical diagnostics requires ongoing investment in research and technology. Does the company finance this through debt? This chart of total market debt helps evaluate its financial strategy.
P/E of the company, segment and market as a whole
P/E - Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company known for its tests for determining genetic predisposition to cancer. This chart shows how investors view its transition to a broader range of genetic tests. The valuation is dependent on competition and insurance reimbursement policies.
P/E of the market segment - Cancer analysis
Myriad Genetics is a molecular diagnostics company that develops and markets genetic tests that help assess disease risk, determine prognosis, and select treatments. This chart shows the average rating for the sector, helping to understand how the market values Myriad's innovative diagnostic products.
P/E of the market as a whole
Myriad Genetics is a pioneering company in genetic testing, known for its cancer predisposition tests. The company faces increasing competition. Does its valuation reflect these challenges, or does it reflect confidence in its ability to innovate and expand into new diagnostic areas, assessing it as a unique case?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Myriad Genetics Inc.
Myriad Genetics is a pioneer in molecular diagnostics, offering genetic tests to determine the risk of hereditary cancer and select optimal treatments. This chart shows future revenue expectations, which depend on the adoption of its tests in clinical practice, testing volumes, and insurance reimbursement levels.
%20P%2FE%20Myriad%20Genetics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Myriad-Genetics-Inc.&v=1772655239278 "Chart of the company's future (projected) P/E Myriad Genetics Inc.")
Future (projected) P/E of the market segment - Cancer analysis
Myriad Genetics is a pioneer in molecular diagnostics and genetic testing, best known for its breast cancer predisposition test (BRACAnalysis). This chart shows forecasts for the medical diagnostics sector. This allows us to assess how the market perceives Myriad's ability to compete in the face of a growing number of players in the genetic testing market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-analysis&v=1772655239302 "Future (projected) P/E graph of the market segment - Cancer analysis")
Future (projected) P/E of the market as a whole
Myriad Genetics, Inc. is a pioneer in genetic testing, particularly for determining hereditary cancer risk. The company is at the center of a revolution in personalized medicine. This market sentiment chart influences how investors evaluate companies whose value is based on cutting-edge scientific technologies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772655239335 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company offering genetic tests to determine the risk of inherited diseases, primarily cancer. Profits are based on the number of tests performed and reimbursements from insurance companies. This graph illustrates how personalized medicine is becoming a commercial reality.
Profit of companies in the market segment - Cancer analysis
Myriad Genetics is a pioneer in genetic testing, offering tests to identify inherited cancer risk and tailor treatment. This chart, reflecting the profitability of the cancer testing sector, demonstrates how personalized medicine is becoming the standard. The growing use of genetic testing in oncology is a key growth driver for Myriad.
Overall market profit
Myriad Genetics is a pioneer in genetic testing, specializing in hereditary cancer diagnostics. Demand for its tests is driven by the adoption of personalized medicine and insurance coverage. Overall economic growth, reflected in this graph, is driving increased healthcare spending and the adoption of innovative diagnostic methods.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Myriad Genetics Inc.
Myriad Genetics is a pioneer in genetic testing, offering tests to determine inherited cancer risk and to help select treatments. The company's future lies in the development of personalized medicine. This chart reflects analysts' forecasts for the volume of tests performed and the introduction of new diagnostic products into medical practice.
%20profit%20of%20the%20company%20Myriad%20Genetics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Myriad-Genetics-Inc.&v=1772655239530 "Graph of future (projected) profit of the company Myriad Genetics Inc.")
Future (predicted) profit of companies in the market segment - Cancer analysis
Myriad Genetics is a molecular diagnostics company offering tests that help assess the risk of developing hereditary diseases, primarily cancer. Its growth depends on the introduction of genetic testing into medical practice. This chart for the medical diagnostics sector reflects expectations for the growth of personalized medicine and the demand for innovative tests.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-analysis&v=1772655239543 "Graph of future (predicted) profits of companies in a market segment - Cancer analysis")
Future (predicted) profit of the market as a whole
Myriad Genetics, a molecular diagnostics company, helps assess the risk of inherited diseases, including cancer. Demand for its tests depends on healthcare budgets and household incomes. This curve, reflecting general economic expectations, indirectly affects the ability of patients and insurance systems to pay for these services.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772655239581 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Myriad Genetics Inc.
Myriad Genetics is a genetic testing and precision medicine company offering tests that assess disease risk and aid in treatment. The chart shows a high valuation for each dollar of its revenue. This reflects investors' faith in the growth of personalized medicine and the value of its diagnostic products for doctors and patients.
P/S market segment - Cancer analysis
Myriad Genetics is a pioneer in genetic testing, helping identify the risks of hereditary diseases, primarily cancer. The company's revenue is driven by the number of tests performed and reimbursements from insurance companies. This chart reflects the average valuation in the sector, providing insight into how investors view Myriad's scientific potential and competitive position.
P/S of the market as a whole
Myriad Genetics is a genetic testing and precision medicine company. It offers tests that help assess disease risk and select optimal treatments, particularly in oncology. This chart, showing average market revenue estimates, helps understand the premium investors are willing to pay for personalized medicine technologies that have the potential to transform healthcare.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Myriad Genetics Inc.
Myriad Genetics is a pioneer in molecular diagnostics, offering genetic tests to determine the risk of inherited diseases, particularly cancer. The company's future depends on innovation. This chart reflects investor expectations for increased testing volumes and the introduction of new diagnostic products into clinical practice.
%20P%2FS%20Myriad%20Genetics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Myriad-Genetics-Inc.&v=1772655239683 "The graph of the company's future (projected) P/S Myriad Genetics Inc.")
Future (projected) P/S of the market segment - Cancer analysis
Myriad Genetics is a leading company in genetic testing and precision medicine. Its tests help assess the risk of developing hereditary diseases, primarily cancer. This chart shows the average estimated future sales in the medical diagnostics sector. It provides insight into how the market perceives Myriad's potential in the growing field of personalized medicine.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-analysis&v=1772655239803 "Future (projected) P/S market segment graph - Cancer analysis")
Future (projected) P/S of the market as a whole
Myriad Genetics is a company specializing in genetic testing that helps identify the risk of hereditary diseases, primarily cancer. The chart below shows how the market views its revenue growth prospects. Myriad's growth reflects the trend toward personalized and preventative medicine, where genetic information is becoming the key to health.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772655239898 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Myriad Genetics Inc.
This chart shows the revenue of Myriad Genetics, a company specializing in genetic testing that helps assess the risk of developing hereditary diseases, primarily cancer. Sales are generated from these tests. The trend reflects the growing demand for personalized medicine and the integration of genetic diagnostics into clinical practice.
Sales of companies in the market segment - Cancer analysis
Myriad Genetics is a pioneer in genetic testing and precision medicine. The company offers tests that help assess the risk of developing hereditary diseases, primarily cancer. This graph shows the growth of the genetic diagnostics market. Myriad's innovations have transformed approaches to prevention and treatment, making personalized medicine a reality for millions of people.
Overall market sales
Myriad Genetics is a company specializing in genetic testing to identify predisposition to hereditary diseases, primarily cancer. Demand for its tests depends on patient awareness and physician recommendations. The overall economic situation, reflected in this chart, influences insurance coverage for these procedures.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company offering genetic tests to determine the risk of hereditary cancer. Future revenue depends on the adoption of its tests in clinical practice. The chart shows analysts' forecasts for growth in the personalized medicine market.
%20sales%20of%20the%20company%20Myriad%20Genetics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Myriad-Genetics-Inc.&v=1772655240195 "Schedule of future (projected) sales of the company Myriad Genetics Inc.")
Future (projected) sales of companies in the market segment - Cancer analysis
Myriad Genetics is a leading company in molecular diagnostics and genetic testing, helping assess the risk of hereditary diseases, primarily cancer. Its tests influence medical decision-making. This chart shows the forecast for the entire cancer testing market, where Myriad is a pioneer and key player.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-analysis&v=1772655240274 "Schedule of future (projected) sales of companies in the market segment - Cancer analysis")
Future (projected) sales of the market as a whole
Myriad Genetics specializes in genetic testing to determine the risk of inherited diseases, primarily cancer. Demand for its tests depends on the development of personalized medicine. This chart shows general economic trends, but for Myriad, demographic shifts, insurance coverage, and scientific discoveries that are changing approaches to disease prevention are more important.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772655240342 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Myriad Genetics Inc.
Myriad Genetics is a pioneer in genetic testing, helping to identify the risk of hereditary diseases, particularly cancer. The company's profitability depends on the number of tests performed and the level of reimbursement from insurance companies. This chart shows how the company monetizes its research and development in the field of personalized medicine.
Market segment marginality - Cancer analysis
Myriad Genetics is a molecular diagnostics company that pioneered genetic testing for hereditary cancer. Profitability depends on testing volume, insurance reimbursement, and competition. This chart shows operating results. Comparisons with other diagnostics companies highlight their history of innovation and current market challenges.
Market marginality as a whole
Myriad Genetics is a pioneer in genetic testing, which helps determine predisposition to hereditary diseases, primarily cancer. Their tests are used to make medical decisions. This overall profitability curve is not important to them. Their business is driven by scientific advances, acceptance of their tests by the medical community, and insurance coverage.
Employees in the company, segment and market as a whole
Number of employees in the company Myriad Genetics Inc.
Myriad Genetics is a pioneer in genetic testing. Its team consists of scientists, laboratory technicians, and genetic counselors. This chart reflects the scale of its laboratory operations and investments in the development of new diagnostic tests that help assess the risk of inherited diseases.
Share of the company's employees Myriad Genetics Inc. within the market segment - Cancer analysis
Myriad Genetics is a pioneer in genetic testing and personalized medicine, helping identify risks for inherited diseases, including cancer. This chart shows the company's scientific expertise in its niche. Behind it lies a large team of scientists and lab technicians who perform complex analyses that provide vital information to patients and doctors.
Number of employees in the market segment - Cancer analysis
Myriad Genetics, Inc. is a pioneer in molecular diagnostics and genetic testing, particularly in oncology. This chart illustrates employment trends in the personalized medicine sector. The growth in the number of geneticists, laboratory technicians, and consultants reflects the growing role of genetic information in medical decision-making, from cancer risk assessment to personalized therapy selection.
Number of employees in the market as a whole
Myriad Genetics is a pioneer in genetic testing, having developed tests to identify inherited cancer risk. The company helps people make important health decisions based on DNA analysis. This figure reflects how the growth of personalized and preventive medicine, driven by Myriad, is creating new jobs in genetics and laboratory diagnostics.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Myriad Genetics Inc. (MYGN)
Myriad Genetics is a company specializing in molecular diagnostics and genetic testing (e.g., cancer tests). This chart reflects the high value of its intellectual capital. Myriad's key assets are its patented tests, technologies, and vast genetic database. The chart shows how highly the market values these knowledge-intensive assets per employee.
%20of%20the%20company%20Myriad%20Genetics%20Inc.%20(MYGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Myriad-Genetics-Inc.-MYGN&v=1772655240898 "Chart of market capitalization per employee (in thousands of dollars) of the company Myriad Genetics Inc. (MYGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer analysis
Myriad Genetics is a company specializing in genetic testing that helps assess the risk of developing hereditary diseases, particularly cancer. Its value lies in its scientific research and databases. This chart demonstrates the high market valuation of its unique diagnostic tests and intellectual property.
%20by%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-analysis&v=1772655240904 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer analysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Myriad Genetics is a leading molecular diagnostics company known for its genetic tests for hereditary cancer risk. This chart shows how the market values this pioneer in personalized medicine. Its high per-employee cost reflects the value of its scientific data, patents, and brand.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772655240942 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Myriad Genetics Inc. (MYGN)
Myriad Genetics is a pioneer in molecular diagnostics, known for its tests for genetic predisposition to cancer (such as BRCA). This graph shows the efficiency of their laboratories: profit per employee depends on the number of tests processed, the average price per test (paid by insurers), and the level of automation in the laboratory.
%20Chart%20Myriad%20Genetics%20Inc.%20(MYGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Myriad-Genetics-Inc.-MYGN&v=1772655240959 "Company Profit Per Employee (in thousands of dollars) Chart Myriad Genetics Inc. (MYGN)")
Profit per employee (in thousands of dollars) in the market segment - Cancer analysis
Myriad Genetics (MYGN) is a pioneer in molecular diagnostics. They are best known for their BRCA (breast cancer risk) test. They are a laboratory business. This metric reflects how efficiently their labs process tests and how well their sales team promotes them to physicians.
%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-analysis&v=1772655240990 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer analysis")
Profit per employee (in thousands of dollars) for the market as a whole
Myriad Genetics is a biotech company, a pioneer in genetic testing (BRCA, for cancer). They provide diagnostic tests. This is an R&D and service business. This chart shows how their tests (margins) are in demand in the face of increasing competition and price pressure from insurance companies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772655241134 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Myriad Genetics Inc. (MYGN)
Myriad Genetics is a molecular diagnostics company offering tests to determine genetic predisposition to cancer. This chart shows the commercial success of its diagnostic products. The growth in revenue per employee reflects the widespread use of its tests in clinical practice and the increasing volume of testing performed.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Myriad-Genetics-Inc.-MYGN&v=1772655241175 "Sales chart per company employee Myriad Genetics Inc. (MYGN)")
Sales per employee in the market segment - Cancer analysis
Myriad Genetics is a pioneer in genetic testing, known for its tests (like MyRisk) for determining hereditary cancer risk. This graph shows the income generated by each employee (geneticist, lab technician, salesperson). This allows us to evaluate their productivity compared to other companies in the genetic testing sector.
Sales per employee for the market as a whole
Myriad Genetics (MYGN) is a molecular diagnostics company known for its genetic tests (for example, for breast cancer risk assessment). It's a knowledge-intensive business. This chart shows how effectively the company monetizes its diagnostic services. Revenue is generated in its laboratories and sold through a network of medical representatives.
Short shares by company, segment and market as a whole
Shares shorted by company Myriad Genetics Inc. (MYGN)
Myriad Genetics, Inc. is a pioneer in molecular diagnostics and genetic testing (e.g., cancer risk testing). The company faces increasing competition and pricing pressure. This chart shows bearish bets from investors who doubt its ability to maintain market share and profitability amid price wars.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Myriad-Genetics-Inc.-MYGN&v=1772655241373 "Short Shares Chart for the Company Myriad Genetics Inc. (MYGN)")
Shares shorted by market segment - Cancer analysis
Myriad Genetics is a pioneer in genetic testing (e.g., BRCA breast cancer risk tests). This indicator measures pessimism. "Short" here is a bet that their "old" tests will lose out to new, cheaper competition, and that insurance companies will reduce reimbursement.
Shares shorted by the overall market
Myriad Genetics is a pioneer in molecular diagnostics, known for its tests for genetic predisposition to cancer. When this chart shows rising fear, investors re-evaluate even established medtech companies. Competition in the testing market and general pessimism are putting pressure on MYGN.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Myriad Genetics Inc. (MYGN)
Myriad Genetics (MYGN) is a molecular diagnostics company best known for its genetic test (BRACAnalysis) for breast and ovarian cancer predisposition. This chart measures sentiment. It shows "overbought" (above 70) on news of new tests or "oversold" (below 30) amid increased competition and price pressure.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Myriad-Genetics-Inc.-MYGN&v=1772655241484 "RSI 14 indicator chart for the company's stock Myriad Genetics Inc. (MYGN)")
RSI 14 Market Segment - Cancer analysis
Myriad Genetics (MYGN) is a pioneer in genetic testing. They were the first to offer a test for the "breast cancer gene" (BRCA). The RSI_14_Seg for "Cancer Analysis" (biotech/diagnostics) shows the overall sentiment. It helps us understand: is MYGN's growth driven by their new tests or is the entire sector overheated by expectations?
RSI 14 for the overall market
Myriad Genetics (MYGN) develops genomic tests. This chart reflects insurance companies' willingness to pay for expensive innovations. During periods of euphoria and budget growth, they more readily approve new tests. During times of panic and cost savings, insurers may tighten requirements, preferring older, cheaper methods.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MYGN (Myriad Genetics Inc.)
Myriad Genetics is a pioneer in molecular diagnostics and genetic testing. The company is known for its tests (myRisk, GeneSight) for determining hereditary cancer risk and selecting treatments. This chart shows the average analyst forecast. Their target price is a collective estimate of future testing volumes and competition.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MYGN-Myriad-Genetics-Inc.&v=1772655241628 "A chart showing analyst consensus forecasts for the expected stock price. MYGN (Myriad Genetics Inc.)")
The difference between the consensus estimate and the actual stock price MYGN (Myriad Genetics Inc.)
Myriad Genetics is a pioneer in genetic testing, known for its BRCA cancer test. The company is currently transforming itself, focusing on new products: a psychiatric test (GeneSight) and prenatal screening. This chart shows the difference between the consensus forecast and the price. It reflects analysts' confidence in the success of this turnaround and the potential of the new tests.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MYGN-Myriad-Genetics-Inc.&v=1772655241803 "A chart showing the difference between the consensus forecast and the actual stock price. MYGN (Myriad Genetics Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer analysis
Myriad Genetics is a pioneer in molecular diagnostics, known for its tests (BRACAnalysis) for determining hereditary cancer risk. This chart shows analysts' overall expectations for the cancer testing sector. It reflects whether experts believe the genetic testing market will grow or see risks in price competition.
Analysts' consensus forecast for the overall market share price
Myriad Genetics is a pioneer in molecular diagnostics, known for its genetic tests (for example, for breast cancer risk). This chart reflects the overall level of confidence in the economy. This is important for Myriad. During a recession (pessimism), patients may postpone preventative (non-urgent) tests, and insurers may put pressure on prices.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Myriad Genetics Inc.
Myriad Genetics is a pioneer in genetic testing. They became known for their breast cancer test (BRACAnalysis) and now offer a broad range of services. This chart is a summary indicator of their transformation. It likely aggregates the volume of their traditional cancer testing, the growth rate of their new products (for example, prenatal screening), and their challenging path to profitability.
AKIMA Market Segment Index - Cancer analysis
Myriad Genetics (MYGN) is a pioneer in genetic diagnostics and a leader in testing (myRisk) for hereditary cancers (BRCA) and mental disorders. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this high-tech diagnostic model (MYGN) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Myriad Genetics is a pioneer in genetic testing and precision medicine (cancer risk assessment, prenatal diagnostics). This chart, reflecting the market average, provides context. It helps assess how Myriad, which is undergoing transformation and growth, compares to the overall economic trends impacting the healthcare sector.
